SP Tulsian, sptulsian.com shares his view on Strides Arcolab and he says that the deal is positive for the company.
Tulsian told CNBC-TV18, "Strides Arcolab, positive deal for the company, because if you see the debt has really piled up a lot in the company's books and if you see this deal maybe Rs 1,750-1,800 crore and as indicated by the management that they are planning to reduce the debt by about USD 250 billion, so that will definitely be bringing down the debt-equity ratio."
He further added, "Apart from that people have lately started comparing Strides Arcolab also on the lines of the Glenmark Pharma that they have these kind of deals in the pipeline and one has really to see whether the such kind of deals, the kind of properties they are holding, whether these kind of deals can also happen in the foreseeable future, maybe in next six to twelve months. So overall positive for the company, because these kinds of deals were getting delayed for last one year or so."
